Vision-related quality of life after surgery for vitreoretinal disorders in a Mexican population: an observational study.

Visual-related quality of life in retinal diseases has not been explored in the Mexican population, so the study aims to identify it in patients undergoing surgery due to advanced diabetic retinopathy, rhegmatogenous retinal detachment, and other causes of vitrectomy; the Visual Function Quality-25 questionnaire was applied to 76 patients, pre-and postoperative. It was divided into 10 domains and interpreted according to the National Eye Institute scores, where the highest value was the best visual function. Student's t-test for related samples and Wilcoxon's t-test were used to compare each domain between measurements, and Pearson's R test to correlate the total score of age and quality of life; a p value < 0.05 was considered significant. Diabetic retinopathy patients showed an improvement 1 and 3 months after surgery in all domains; in rhegmatogenous retinal detachment, there was an improvement observed up to 3 months, while a decrease in ocular pain was observed in other causes of vitrectomy. Differences found in all the quality-of-life scores were not statistical, but clinically significant. The study shows that visual-related quality of life domains improves after vitrectomy; the inclusion of this analysis might be considered relevant within the parameters of surgical success of the most prevalent vitreoretinal diseases.

Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections.

OBJECTIVE: Subconjunctival hemorrhage (SCH) is an important minor side effect that might affect patient compliance to antivascular endothelial growth factor (anti-VEGF) intravitreal injection treatment (IVI). We sought to compare SCH incidence and pain score responses after topical oxymetazoline in naïve patients undergoing a single IVI of ranibizumab for diabetic macular edema. METHODS: Prospective, randomized, double-blinded, single centre study. One hundred two patients naïve to anti-VEGF were assigned to receive either topical oxymetazoline or placebo 30 minutes before IVI. SCH incidence and area were measured by slit lamp 24 hours after, and pain was evaluated 5 minutes and 24 hours after. RESULTS: SCH incidence was reported on 72% in control group versus 51% in oxymetazoline group (p = 0.037). Mean size of SCH was 16.82 mm2 in control group versus 12.55 mm2 in oxymetazoline group (p = 0.394). Prevalence of local pain in the overall study population was 60%. No significant statistical difference was achieved between groups 5 minutes or 24 hours after IVI in either pain scale evaluation. CONCLUSION: Administration of topical oxymetazoline 30 minutes before IVI is a single, harmless, cost-effective intervention that decreases the incidence of subconjunctival hemorrhage. This may considerably improve patient treatment satisfaction and promote compliance to IVI therapy.